Speaker(s): 

Stacy L. Andersen, Staff Member, Geisinger - has nothing to disclose.

Atul Bali, MD, Staff Member, Geisinger - has nothing to disclose.

Alexander Chang, MD, MS, Staff Member, Geisinger - Research Grant: Novartis/Boehringer-Ingelheim/Bayer/Vertex

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the stages of blood pressure control according to the 2025 ACC/AHA Hypertension guidelines.
• Name the blood pressure target for maximal risk reduction per the 2025 ACC/AHA Hypertension guidelines and which patients need immediate antihypertensive therapy.
• List the concept behind each letter of MAP BP and define how these concepts apply in the care of our patients.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anne Gallagher, MHSA - Activity Director, Rebecca Slangan, MBA - Activity Director, Kelly Shaw, PsyD, Brian J. Piper, PhD, Daniel Longyhore, PharmD, EdD, Lauren Weaver-, MSN, Valencia Walker, MD, MPH, MaryAnn Babinski, Dorca Serrano, Amanda Caleb, PhD, Alejandra Marroquin, MSW, have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Dr. Chang disclosed active research grant relationships with Novartis, Boehringer Ingelheim, Bayer, and Vertex. Because the educational topic relates to hypertension care, these relationships were deemed relevant. Dr. Chang did not serve as a speaker and did not have sole control over content development. Independent review and guideline alignment were used to ensure balance, objectivity, and independence. The conflict was mitigated and did not preclude Dr. Chang’s involvement.

Commercial Support for this Session

None